Kaiser Poll Show Support for Personal Imporatation

Kaiser Poll Show Support for Personal Imporatation

Saturday, June 17, 2017

Making the case for Personal Importation as a tool to lower drug costs—an open appeal to President Trump as he formulates executive orders

(Part 1 of 2-parts: )

President Donald Trump, whose administration has been hamstrung in keeping one of his most significant campaign pledges—to lower the cost of prescription medicines--, now has apparently decided to take the course of issuing executive orders to end the tragedy  that continues to plague American patients, namely living in the country with the highest costs prescription medicines of any industrialized nation in the world and being denied access to vital medicines.

We have issued news releases and blogs urging that the President take such action, and move it out of the purview of members of the U.S. Congress who receive millions of dollars from Pharma in campaign contributions. 

At the same time, we believe the President must accept some of the burden of the blame for the inaction.  He has appointed a Health and Human Services Secretary, former Representative Tom Price, who is decidedly pro-Pharma, and who, many believe, even profited from stock purchases of a Pharma stock that increased tremendously in value based upon inside knowledge.

Also, the President’s appointee (Scott Gottlieb) as Commissioner of the Food and Drug Administration (FDA), apparently believes that the ‘free market’ is the primary tool to lower the costs of over-priced medicines, and opposes personal importation of safe, affordable brand-name medicines from licensed, registered pharmacies in Tier One Countries whose standards of safety and efficacy meet or exceed those of the U.S. He also opposes negotiation by the government with Pharma, choosing instead to look to stepped-up introduction of generics as the primary route to lowering the costs of medicines.

As for Congress, it continues to stumble along with plan after plan, proposed legislation, including the fatally flawed S. 469, hailed by many Democrats as the save-all concept to lower prescription drug costs.  The bill is based upon an equally flawed effort of 2003 when it was first introduced. The legislation has already raised vigorous opposition among groups not only in the U.S. but also in Canada because it would impose U.S. oversight on Canadian-based operations such as provincial licensing authorities in Canada, and even Health Canada.

This is more than unfortunate, it is tragic because it illustrates what can only be considered the politicalization of an important American healthcare issues, e.g., the beneficial impact upon the health and well-being of American patients from access to adherence to a regimen of authentic prescription medicines.

The estimates vary, but the undeniable fact is that millions of American patients forego such adherence simply because the medicines themselves are so high-priced that they are unaffordable, making them, in and of themselves, unavailable.

While we are faced with the spectacle of an ineffective response from Congress, which continues to offer narrowly defined proposals ranging from personal importation to transparency to more generics to penalties for Pharma price gouging , and conducting time-consuming hearings that result in nothing, while Pharma continues to thumb its collective nose to the American people and set prices beyond the reach of patients.

At the same time, a score of group and organizations issue periodic statements, collective letters and develop positions that address the costs and availability of medicines that costs thousands of dollars, all the while ignoring the fact that these commendable efforts are not mutually exclusive from the inclusion as part of recognition of the harmful impact of lack of access to any medicine, and that an unaffordable maintenance medicine is just as unavailable to untold numbers of patients  as a medicine that costs $120,000 a year.

As an advocate for role for Personal Importation of brand-name prescription medicines, and as a supporter of a comprehensive approach to address all elements of the negative impact of Pharma pricing abuses, and the rapidly evolving record of abuses by huge pharmacy benefit managers, I believe it is tragic that the discussion about the costs and availability of any medicine has become so highly segmented. 

That is why it is incumbent upon the President to provide  leadership by creating policies that will result in a truly comprehensive solution with personal importation being recognized as not only a part of his strategies, but as the only offering a degree of immediate relief to the dilemma of 55 million Americans not being able to afford their medications.

While many of the challenges of new medicines, value, and prices will be met in the future, the fact is that personal importation is a readily, safe available strategy that has already been embraced by millions of Americans, and has received support from policy-makers at local, state and Federal levels, even in the face of Pharma opposition and Congressional inaction!

Why then, has the personal importation of safe, brand-name medicines from licensed registered pharmacies in Tier One Countries whose standards of safety and efficacy meet or exceed those of the U.S. not become a part of the solution when an examination of the facts makes the case for such a strategy from to allow personal importation of prescription and offer benefits to the health and well-being of Americans.

For more than a quarter-century, Americans have been victims of the predatory pricing practices of Pharma. 

        Americans pay the highest prescription prices in the industrial world

        This is based upon a national policy of allowing the industry to ‘charge what the traffic will bear’

        The Pharmaceutical Industry has created alliances, influenced governmental policy, colluded with regulatory agencies designed to ensure prices are affordable, and literally ‘bought’ overwhelmed the U.S. Congress with the most contributions of any industry segment in the U.S.

        Result #1—A denial for an estimated 55 million Americans to be able to exercise their right to the health benefit made possible from access to a regimen of vital life-line medicines, simply because they are unaffordable

        Result # 2—The ‘hoped-for’ answer to the scourge of unaffordable medicines—generic medicines—have seen price spikes that have made many of them equally unavailable to American patients.

        Result # 3—Literally millions of Americans suffer from diseases—many of them life-threatening—raising the question of a possible link to the cause-effect impact of unaffordable but vital maintenance medicines that could have benefitted patients  and deterred the harmful effects of their disease.

        Result # 4—Pharma raises prices, on specialty medicines to thousands of dollars for treatments, even though many of the costly medicines are older, lower-cost medicines, and manufacturers are simply taking advantage of the illness of Americans.

        Result # 5—Congress becomes indignant, holds hearings, witness testify, advocacy groups coalesce to ‘address’ price challenges, but…prices remain high, Congress continues with more hearings…and Americans continue to pay the highest prices in the world…WHY?

        RESULT #6--Because Pharma and its allies in the House of Representatives and the U.S. Senate who are the beneficiaries of Pharma’s extensive contributions have controlled the discussion on how to lower prescription and health care costs while Pharma continues to rake in obscene profits, and American patients continue to be denied their medicines.

It is time for a change!  American patients can’t wait any longer!

No comments: